Home » The Effectiveness of Isoxsuprine in Patients With Intermittent Claudication

TITLE

The Effectiveness of Isoxsuprine in Patients With Intermittent Claudication

AUTHOR(S)

Skotnicki, S. H.; van Gaal, G.; Wijn, P. F. F.

PUB. DATE

November 1984

SOURCE

Angiology;Nov1984, Vol. 35 Issue 11, p685

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Sixty male patients with intermittent claudication were investigated in a randomized, double-blind, placebo-controlled study in order to determine the effectiveness of Isoxsuprine. The analysis of the results was made on the basis of subjective assessment of symptoms by the patients themselves and also on the results of segmental blood- pressure measurements and ankle/arm indices at rest and after standardised exercise. Significant differences were demonstrated between the active and placebo groups as regards pain-free walking distance although arterial pressure measurements did not show statistically significant differences between the two groups. Isoxsuprine appears to be significantly beneficial only for patients with ob- structions at the femoro-popliteal level.

Pentoxifylline, a methyl xanthine analogue was evaluated for treatment of intermittent claudication in a double-blind placebo controlled parallel group study in seven centers in the United States. Tests were performed on 128 cases, including 42 who took pentoxifylline (600 mg by mouth daily,...

The present study reports on the effects of a physical treatment modality in patients with intermittent claudication. During this treatment a major part of the skin surface is subjected to intermittent suction and pressure. In a previous, preliminary study the authors found a beneficial effect...

Treadmill testing is frequently used to assess the functional capacity of patients with claudication, but the optimal application of treadmill testing in the setting of multicenter clinical trials remains uncertain. The current study used data from a recent clinical trial of the drug NM-702,...

A double-blind, placebo-controlled, parallel groups study design was utilized to evaluate the efficacy and the safety of papaverine HCL (PA, 300-1,500 mg/day) in the treatment of intermittent claudication. The study was in two phases: Phase 1-6 weeks duration with treadmill claudication tests...

The clinical effect of verapamil was tested in 24 patients with intermittent claudication in a randomized, placebo-controlled, double-blind, crossover study. Slow-release verapamil or placebo was given for two periods of three weeks. The walking distance, systemic blood pressure, and...

Several oral "vasoactive" drugs claim to increase walking capacity in patients with intermittent claudication (IC). Naftidrofuryl, cilostazol, buflomedil, and pentoxifylline are the most studied molecules. Although spanning several decades, several studies underlying these claims were not...

Naftidrofuryl (PraxileneÂ®) is a vasodilator that has been used in the treatment of intermittent claudication for >30 years in Europe to improve walking distance and provide symptomatic relief. However, earlier trials had inconsistencies in design and the clinical relevance of the treatment...

Many patients with peripheral arterial disease (PAD) undergo peripheral bypass surgery to relieve the symptom of intermittent claudication. However, measurement of graft patency alone, assessed by change in ankle blood pressure, may not adequately reflect the improvement in functional status...